Paper - WANFANG MED ONLINE

You Position: Home > Paper

Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

( views:436, downloads:422 )

Author:: No author available

Journal Title:: Chinese Journal of Obstetrics and Gynecology

Issue:: 1

DOI:: 10.3760/cma.j.issn.0529-567X.2020.01.003

Key Word:: 卵巢过度刺激综合征;黄体期;来曲唑;促性腺激素释放激素;随机对照试验;Ovarian hyperstimulation syndrome;Luteal phase;Letrozole;Gonadotropin- releasing hormone;Randomized controlled trial

Abstract： Objective:To explore and compare the preventive effect of using letrozole and gonadotropin-releasing hormone (GnRH) antagonist during luteal phase of patients at high risk for ovarian hyperstimulation syndrome (OHSS).Methods:A total of 99 infertile women undergoing in vitro fertilization and embryo transfer or intracytoplasmic sperm injection with high risk for OHSS were enrolled in this randomized controlled trial.The letrozole group ( n=51) received letrozole of 7.5 mg daily for 3 days;the GnRH antagonist group ( n=48) were given cetrorelix of 0.25 mg subcutaneously daily for 3 days. Both groups received support therapy combined with embryo cryopreservation. The incidence of OHSS was surveyed. And the serum concentration of estradiol, LH and progesterone on days 3, 5 and 8 after oocytes retrieval were measured. Results:There were no statistical differences in terms of baseline characteristics of patients and outcomes of controlled ovarian hyperstimulation between the two groups.The incidence of moderate and severe OHSS was found no significantly difference between letrozole group [11.8%(6/51)] and GnRH antagonist group [10.4%(5/48); P>0.05]. The estradiol concentration of the indicated days on days 3,5 and 8 after oocytes retrieval in letrozole group and GnRH antagonist group were (1 417±3 543) versus (15 210±9 921) pmol/L, (1 692±4 330) versus (18 680±11 567) pmol/L, (239±336) versus (3 582±5 427) pmol/L, respectively;compared with GnRH antagonist group, the estradiol level was significantly lower in the letrozole group (all P<0.01). The luteinizing hormone level in the letrozole group were (0.46±0.40), (0.56±0.55)and (0.67±0.58) U/L on days 3,5 and 8 after oocytes retrieval, which were significantly higher than those of GnRH antagonist group [(0.28±0.28), (0.30±0.19) and (0.45±0.37) U/L, respectively; all P<0.05]. There was no obvious differences on progesterone levels between letrozole group and GnRH antagonist group (all P>0.05),and on days 8 after oocytes retrieval,the level of progesterone in each group were significantly lower than those on day 3 and 5 after oocytes retrieval ( P<0.05). Conclusion:Letrozole has the same efficiency as GnRH antagonist for the prevention of OHSS, faster and cheaper to use, but its efficacy seems not to be related to the suppression of steroidogenic during the luteal phase.

Reference

[1]王培,凌秀凤,李秀玲,等.促性腺激素释放激素拮抗剂在防治卵巢过度刺激综合征中的应用[J].2013,(19).
[2]何巧花,徐嘉宁,崔世红,等.取卵后应用来曲唑与发生早发型卵巢过度刺激综合征的关系[J].2014,(12).
[3]Mai, Qingyun,Hu, Xiaokun,Yang, Gang,etc.Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial[J].2017,216(1).
[4]A. Villasante,A. Pacheco,A. Ruiz,etc.Vascular Endothelial Cadherin Regulates Vascular Permeability: Implications for Ovarian Hyperstimulation Syndrome[J].2006,92(1).
[5]GT Lainas,EM Kolibianakis,IA Sfontouris,etc.Serum vascular endothelial growth factor levels following luteal gonadotrophin‐releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome[J].2014,121(7).
[6].Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study.[J].2017,17(1).
[7]Donoso P,Smitz J,Fatemi HM,etc.Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors.[J].2008,17(3).
[8]He, Qiaohua,Liang, Linlin,Zhang, Cuilian,etc.Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval[J].2014,60(6).
[9]Mor, Yechiel S.,Schenker, Joseph G..Ovarian Hyperstimulation Syndrome and Thrombotic Events[J].2014,72(6).
[10]H E, Guerrero,P, Stein,R H, Asch,etc.Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells.[J].1993,59(4).
[11]Dror Meirow,Joseph G. Schenker,Ariel Rosler.Endocrinology: Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17α-hydroxylase, 17,20-lyase deficiency: what is the role of oestrogens?[J].1996,11(10).
[12]张宇晖,何巧花,李杭生.不同剂量来曲唑预防早发型卵巢过度刺激综合征的临床研究[J].2016,(9).
[13]Selma, Mourad,Julie, Brown,Cindy, Farquhar.Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.[J].2017,1(Spec ).
[14]Devroey P,Polyzos NP,Blockeel C.An OHSS-Free Clinic by segmentation of IVF treatment.[J].2011,26(10).
[15]TG Lainas,IA Sfontouris,IZ Zorzovilis,etc.Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist[J].2007,15(4).
[16]Griesinger G.Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.[J].2010,28(6).
[17]Ashrafi, Mahnaz,Bahmanabadi, Akram,Akhond, Mohammad Reza,etc.Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model[J].2015,292(5).
[18]Zeng, Cheng,Shang, Jing,Jin, Ao-Ming,etc.The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study[J].2019,300(1).
[19]Fatemi,H.M.,Popovic-Todorovic,B.,Humaidan,P.,etc.Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol[J].2014,101(4).
[20]Santos-Ribeiro, Samuel,Polyzos, Nikolaos P.,Stouffs, Katrien,etc.Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition[J].2015,32(7).
[21]Deng Ling,Li Xue-lan,Ye De-sheng,etc.A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL[J].2019,39(2).
[22]Mahajan, Nalini.Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis.[J].2015,8(4).
[23]刘风华,杨业洲,张松英,等.辅助生殖技术并发症诊断及处理共识[J].2015,(7).
[24]Nastri, C. O.,Teixeira, D. M.,Moroni, R. M.,etc.Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention[J].2015,45(4).
[25]Ya-Qin, Wang,Jin, Luo,Wang-Min, Xu,etc.Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?[J].2015,8.
[26]田革联,符淳,余立,等.不同剂量来曲唑预防OHSS发生的效果及对血清VEGF、IL-6、激素及M-α2水平的影响[J].2018,(22).
[27]Bonilla Musoles FM,Raga F,Castillo JC.High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.[J].2009,36(2).
[28]Lainas GT,Zorzovilis IZ,Sfontouris IA,etc.Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol.[J].2009,18(1).
[29]Sahin, Nur,Apaydin, Nesin,Toz, Emrah,etc.Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome[J].2016,293(5).
[30]Hesham G, Al-Inany,Mohamed A, Youssef,Reuben Olugbenga, Ayeleke,etc.Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.[J].2016.